SCHEMBL17902702

SCHEMBL17902702

Cc1ccc(C(=O)Oc2ccc3oc4ccccc4c3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
GAA P10253 2/20 0.59
KMT2A Q03164 2/20 0.55
GBA1 P04062 1/20 0.55
ALDH1A1 P00352 3/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
CYP2C19 P33261 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
HPGD P15428 1/20 0.55
LMNA P02545 2/20 0.52
BCAT1 P54687 1/20 0.51
KDM4E B2RXH2 1/20 0.50
GLA P06280 1/20 0.50
NPBWR1 P48145 1/20 0.50
MAOA P21397 3/20 0.49
MAOB P27338 2/20 0.49
PTGER4 P35408 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19077934 0.89 NPC1 (0.55) MAPTGAAKMT2AGBA1ALDH1A1
SCHEMBL17902686 0.87 KMT2A (0.53) MAPTGAAKMT2AALDH1A1SMN1; SMN2
SCHEMBL17902701 0.87 KMT2A (0.50) MAPTGAAKMT2AALDH1A1NPC1
SCHEMBL19077940 0.84 LMNA (0.50) MAPTGAAKMT2AALDH1A1NPC1
SCHEMBL19490486 0.84 MAPT (0.48) MAPTGAAKMT2AALDH1A1NPC1
SCHEMBL17902684 0.83 KMT2A (0.51) MAPTGAAKMT2AALDH1A1NPC1
SCHEMBL17898566 0.82 MAPT (0.53) MAPTGAAKMT2AALDH1A1RAB9A
SCHEMBL11802887 0.82 LMNA (0.67) MAPTKMT2AALDH1A1NPC1RAB9A
SCHEMBL17902689 0.81 MAPT (0.50) MAPTGAAALDH1A1NPC1RAB9A
SCHEMBL17898591 0.80 MAPT (0.55) MAPTGAAKMT2AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9795586-B2 HNF4-α antagonist and use thereof NATIONAL CANCER CENTER (KR) 2017-10-24 US disclosed
US-20170189371-A1 HNF4-alpha ANTAGONIST AND USE THEREOF NATIONAL CANCER CENTER (KR) 2017-07-06 US disclosed
US-20160193238-A1 HNF4-alpha ANTAGONIST AND USE THEREOF NATIONAL CANCER CENTER (KR) 2016-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189371-A1 HNF4-alpha ANTAGONIST AND USE THEREOF HNF4A, TCF4, WNT3A MAPT 4620/4885GAA 1605/4885KMT2A 1796/4885
US-20160193238-A1 HNF4-alpha ANTAGONIST AND USE THEREOF HNF4A, TCF4, WNT3A MAPT 4620/4885GAA 1605/4885KMT2A 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.